Compare · NRXS vs TMDX
NRXS vs TMDX
Side-by-side comparison of Neuraxis Inc. (NRXS) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NRXS and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.65B, about 27.3x NRXS ($97.2M).
- Over the past year, NRXS is up 103.7% and TMDX is down 40.9% - NRXS leads by 144.6 points.
- NRXS has been more active in the news (7 items in the past 4 weeks vs 2 for TMDX).
- TMDX has more recent analyst coverage (20 ratings vs 0 for NRXS).
- Company
- Neuraxis Inc.
- TransMedics Group Inc.
- Price
- $7.70-1.03%
- $70.82-7.52%
- Market cap
- $97.2M
- $2.65B
- 1M return
- +0.26%
- -18.36%
- 1Y return
- +103.70%
- -40.92%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- AMEX
- NASDAQ
- IPO
- 2023
- 2019
- News (4w)
- 7
- 2
- Recent ratings
- 0
- 20
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest NRXS
- NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives
- SEC Form 8-K filed by Neuraxis Inc.
- SEC Form 4 filed by Neuraxis Inc.
- SEC Form 4 filed by Neuraxis Inc.
- SEC Form 4 filed by Neuraxis Inc.
- SEC Form 3 filed by new insider Blanchard Craig Thomas
- NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
- NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives
- NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference
- iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026
Latest TMDX
- Barclays initiated coverage on TransMedics Group with a new price target
- SEC Form 3 filed by new insider Araujo Fernando N.
- Director Weill David bought $109,058 worth of shares (1,336 units at $81.63), increasing direct ownership by 9% to 16,392 units (SEC Form 4)
- TransMedics Group Inc. filed SEC Form 8-K: Regulation FD Disclosure
- TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
- TransMedics to Present at Upcoming September Investor Conferences
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results